Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find out why I rate HALO stock a Buy.

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products formulated using its Enhanze drug delivery technology. The company now estimates ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of ...

Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug delivery technology for subcutaneous use in most ...

It has been less than two months since my previous article on Halozyme Therapeutics (NASDAQ:HALO), where I highlighted the company's impressive Q3 earnings and recapped my views on the company's ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical are part of the Zacks Screen of the Week article.